文献速递妇科肿瘤

多塔利单抗联合尼拉帕利一线治疗晚期卵巢癌

Dostarlimab and niraparib in primary advanced ovarian cancer.
PubMed 文献 · Ann Oncol · 2025-06-02

FIRST/ENGOT-OV44 III期随机双盲试验在1138例新诊断III-IV期上皮性卵巢癌患者中比较含多塔利单抗方案(第3组)与对照方案(第2组)。中位随访53.1个月,第3组中位无进展生存期20.6个月对比第2组19.2个月(HR 0.85,95%CI 0.73-0.99,P=0.0351),总生存期无统计学显著差异(中位44.4对比45.4个月,HR 1.01,95%CI 0.86-1.19,P=0.9060)。

要点

  • 多塔利单抗联合铂类化疗及尼拉帕利维持使中位无进展生存期由19.2个月延长至20.6个月(HR 0.85)。
  • 总生存期成熟度57%,两组中位总生存期44.4个月对比45.4个月,无统计学显著差异(HR 1.01)。
  • 毒性谱与所用药物已知安全性特征一致。

核心结论

  • 在晚期卵巢癌一线治疗中,在铂类化疗和尼拉帕利维持基础上加用多塔利单抗与统计学显著但临床幅度有限的无进展生存期改善相关,总生存期无差异。

研究设计与样本

  • 随机、双盲、III期FIRST/ENGOT-OV44试验,新诊断III-IV期上皮性卵巢癌患者按1:2随机分配至第2组(铂类化疗-安慰剂联合尼拉帕利维持)或第3组(铂类化疗-多塔利单抗联合多塔利单抗-尼拉帕利维持)。
  • 第1组(铂类化疗-安慰剂联合安慰剂维持)在PARP抑制剂获批后终止入组;疗效在意向治疗人群的第2组和第3组中评估。
  • 2018年11月14日至2021年1月5日,1138例患者随机分配至第2组(n=385)和第3组(n=753)并纳入疗效分析;安全性在至少接受一剂研究治疗的患者中评估(第1-3组,按实际治疗分析)。

主要发现

  • 中位随访53.1个月(四分位距47.5-59.7)。
  • 第3组对比第2组的中位无进展生存期为20.6个月对比19.2个月(HR 0.85,95%CI 0.73-0.99,P=0.0351),差异有统计学意义。
  • 总生存期成熟度57%,第3组对比第2组中位总生存期为44.4个月对比45.4个月(HR 1.01,95%CI 0.86-1.19,P=0.9060),无统计学显著差异。
  • 观察到的毒性反应与所用药物已知安全性特征一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The combination of immunotherapies and poly (ADP-ribose) polymerase inhibitors (PARPis) has been hypothesized to improve outcomes in advanced ovarian cancer (aOC). The FIRST/ENGOT-OV44 trial evaluated adding dostarlimab to first-line platinum-based chemotherapy (PBCT) and niraparib maintenance ± bevacizumab in patients with aOC. PATIENTS AND METHODS: In this randomized, double-blind, phase III trial, patients with newly diagnosed stage III-IV epithelial OC were randomized (1:2) to arm 2 (PBCT-placebo with niraparib maintenance) or arm 3 (PBCT-dostarlimab with dostarlimab-niraparib maintenance); arm 1 (PBCT-placebo with placebo maintenance) enrollment terminated following PARPi approvals. Efficacy was assessed in arms 2 and 3 (intention-to-treat population). The primary endpoint was investigator-assessed progression-free survival (PFS) as per RECIST v1.1. The key secondary endpoint was overall survival (OS). Safety was assessed in patients who received one or more doses of study treatment (arms 1-3; analyzed as per treatment received). RESULTS: From 14 November 2018 to 5 January 2021, 1138 patients were randomized to arms 2 (n = 385) and 3 (n = 753) and included in efficacy analyses. Median follow-up was 53.1 (interquartile range 47.5-59.7) months. There was a statistically significant difference in PFS in arm 3 versus arm 2 (median 20.6 versus 19.2 months; hazard ratio [HR] 0.85, 95% confidence interval [CI] 0.73-0.99, P = 0.0351). OS had reached 57% maturity and was not statistically significant (median 44.4 versus 45.4 months; HR 1.01, 95% CI 0.86-1.19, P = 0.9060). Toxicities observed were consistent with known safety profiles of the agents used in the study. CONCLUSIONS: In the first-line treatment of patients with aOC, the addition of dostarlimab to PBCT and niraparib maintenance was associated with a statistically significant, but clinically modest, PFS improvement, with no difference in OS.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Hardy-Bessard AC, Pujade-Lauraine E, Moore RG, et al. Dostarlimab and niraparib in primary advanced ovarian cancer. Ann Oncol. 2025. PMID: 40461381. doi:10.1016/j.annonc.2025.05.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。